Clinical trial

Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy

NCT02628106

Study summary

ClinicalTrials.gov

Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Lipo-PGE1 Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-12-01

PhasePHASE4

Conditions

Diabetic Nephropathyverified · MONDO: diabetic kidney disease

Interventions

Lipo-PGE1DRUG

Sponsors & collaborators

West China Hospitallead sponsor

Mapped research locations

ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02628106 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.